Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas

Rebekah R. White, Herbert I. Hurwitz, Michael A. Morse, Catherine Lee, Mitchell S. Anscher, Erik K. Paulson, Marcia R. Gottfried, John Baillie, Malcolm S. Branch, Paul S. Jowell, Kevin M. McGrath, Bryan M. Clary, Theodore N. Pappas, Douglas Tyler

Research output: Contribution to journalArticle

173 Citations (Scopus)

Abstract

Background: The use of neoadjuvant (preoperative) chemoradiotherapy (CRT) for pancreatic cancer has been advocated for its potential ability to optimize patient selection for surgical resection and to downstage locally advanced tumors. This article reports our experience with neoadjuvant CRT for localized pancreatic cancer. Methods: Since 1995, 111 patients with radiographically localized, pathologically confirmed pancreatic adenocarcinoma have received neoadjuvant external beam radiation therapy (EBRT; median, 4500 cGy) with 5-flourouracil-based chemotherapy. Tumors were defined as potentially resectable (PR, n = 53) in the absence of arterial involvement and venous occlusion and locally advanced (LA, n = 58) with arterial involvement or venous occlusion by CT. Results: Five patients (4.5%) were not restaged due to death (n = 3) or intolerance of therapy (n = 2). Twenty-one patients (19%) manifested distant metastatic disease on restaging CT. Twenty eight patients with initially PR tumors (53%) and 11 patients with initially LA tumors (19%) were resected after CRT. Histologic examination revealed significant fibrosis in all resected specimens and two complete responses. Surgical margins were negative in 72%, and lymph nodes were negative in 70% of resected patients. Median survival in resected patients has not been reached at a median follow-up of 16 months. Conclusions: Neoadjuvant CRT provided an opportunity for patients with occult metastatic disease to avoid the morbidity of resection and resulted in tumor downstaging in a minority of patients with LA tumors. Survival after neoadjuvant CRT and resection appears to be at least comparable to survival after resection and adjuvant (postoperative) CRT.

Original languageEnglish (US)
Pages (from-to)758-765
Number of pages8
JournalAnnals of Surgical Oncology
Volume8
Issue number10
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Pancreas
Adenocarcinoma
Chemoradiotherapy
Neoplasms
Pancreatic Neoplasms
Survival
Adjuvant Chemoradiotherapy
Patient Selection
Fibrosis
Radiotherapy
Lymph Nodes
Morbidity
Drug Therapy

Keywords

  • Adenocarcinoma
  • Chemoradiotherapy
  • Neoadjuvant therapy
  • Pancreas

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

White, R. R., Hurwitz, H. I., Morse, M. A., Lee, C., Anscher, M. S., Paulson, E. K., ... Tyler, D. (2001). Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Annals of Surgical Oncology, 8(10), 758-765. https://doi.org/10.1245/aso.2001.8.10.758

Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. / White, Rebekah R.; Hurwitz, Herbert I.; Morse, Michael A.; Lee, Catherine; Anscher, Mitchell S.; Paulson, Erik K.; Gottfried, Marcia R.; Baillie, John; Branch, Malcolm S.; Jowell, Paul S.; McGrath, Kevin M.; Clary, Bryan M.; Pappas, Theodore N.; Tyler, Douglas.

In: Annals of Surgical Oncology, Vol. 8, No. 10, 2001, p. 758-765.

Research output: Contribution to journalArticle

White, RR, Hurwitz, HI, Morse, MA, Lee, C, Anscher, MS, Paulson, EK, Gottfried, MR, Baillie, J, Branch, MS, Jowell, PS, McGrath, KM, Clary, BM, Pappas, TN & Tyler, D 2001, 'Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas', Annals of Surgical Oncology, vol. 8, no. 10, pp. 758-765. https://doi.org/10.1245/aso.2001.8.10.758
White RR, Hurwitz HI, Morse MA, Lee C, Anscher MS, Paulson EK et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Annals of Surgical Oncology. 2001;8(10):758-765. https://doi.org/10.1245/aso.2001.8.10.758
White, Rebekah R. ; Hurwitz, Herbert I. ; Morse, Michael A. ; Lee, Catherine ; Anscher, Mitchell S. ; Paulson, Erik K. ; Gottfried, Marcia R. ; Baillie, John ; Branch, Malcolm S. ; Jowell, Paul S. ; McGrath, Kevin M. ; Clary, Bryan M. ; Pappas, Theodore N. ; Tyler, Douglas. / Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. In: Annals of Surgical Oncology. 2001 ; Vol. 8, No. 10. pp. 758-765.
@article{75395db6d80348959162e2290d0fd976,
title = "Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas",
abstract = "Background: The use of neoadjuvant (preoperative) chemoradiotherapy (CRT) for pancreatic cancer has been advocated for its potential ability to optimize patient selection for surgical resection and to downstage locally advanced tumors. This article reports our experience with neoadjuvant CRT for localized pancreatic cancer. Methods: Since 1995, 111 patients with radiographically localized, pathologically confirmed pancreatic adenocarcinoma have received neoadjuvant external beam radiation therapy (EBRT; median, 4500 cGy) with 5-flourouracil-based chemotherapy. Tumors were defined as potentially resectable (PR, n = 53) in the absence of arterial involvement and venous occlusion and locally advanced (LA, n = 58) with arterial involvement or venous occlusion by CT. Results: Five patients (4.5{\%}) were not restaged due to death (n = 3) or intolerance of therapy (n = 2). Twenty-one patients (19{\%}) manifested distant metastatic disease on restaging CT. Twenty eight patients with initially PR tumors (53{\%}) and 11 patients with initially LA tumors (19{\%}) were resected after CRT. Histologic examination revealed significant fibrosis in all resected specimens and two complete responses. Surgical margins were negative in 72{\%}, and lymph nodes were negative in 70{\%} of resected patients. Median survival in resected patients has not been reached at a median follow-up of 16 months. Conclusions: Neoadjuvant CRT provided an opportunity for patients with occult metastatic disease to avoid the morbidity of resection and resulted in tumor downstaging in a minority of patients with LA tumors. Survival after neoadjuvant CRT and resection appears to be at least comparable to survival after resection and adjuvant (postoperative) CRT.",
keywords = "Adenocarcinoma, Chemoradiotherapy, Neoadjuvant therapy, Pancreas",
author = "White, {Rebekah R.} and Hurwitz, {Herbert I.} and Morse, {Michael A.} and Catherine Lee and Anscher, {Mitchell S.} and Paulson, {Erik K.} and Gottfried, {Marcia R.} and John Baillie and Branch, {Malcolm S.} and Jowell, {Paul S.} and McGrath, {Kevin M.} and Clary, {Bryan M.} and Pappas, {Theodore N.} and Douglas Tyler",
year = "2001",
doi = "10.1245/aso.2001.8.10.758",
language = "English (US)",
volume = "8",
pages = "758--765",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas

AU - White, Rebekah R.

AU - Hurwitz, Herbert I.

AU - Morse, Michael A.

AU - Lee, Catherine

AU - Anscher, Mitchell S.

AU - Paulson, Erik K.

AU - Gottfried, Marcia R.

AU - Baillie, John

AU - Branch, Malcolm S.

AU - Jowell, Paul S.

AU - McGrath, Kevin M.

AU - Clary, Bryan M.

AU - Pappas, Theodore N.

AU - Tyler, Douglas

PY - 2001

Y1 - 2001

N2 - Background: The use of neoadjuvant (preoperative) chemoradiotherapy (CRT) for pancreatic cancer has been advocated for its potential ability to optimize patient selection for surgical resection and to downstage locally advanced tumors. This article reports our experience with neoadjuvant CRT for localized pancreatic cancer. Methods: Since 1995, 111 patients with radiographically localized, pathologically confirmed pancreatic adenocarcinoma have received neoadjuvant external beam radiation therapy (EBRT; median, 4500 cGy) with 5-flourouracil-based chemotherapy. Tumors were defined as potentially resectable (PR, n = 53) in the absence of arterial involvement and venous occlusion and locally advanced (LA, n = 58) with arterial involvement or venous occlusion by CT. Results: Five patients (4.5%) were not restaged due to death (n = 3) or intolerance of therapy (n = 2). Twenty-one patients (19%) manifested distant metastatic disease on restaging CT. Twenty eight patients with initially PR tumors (53%) and 11 patients with initially LA tumors (19%) were resected after CRT. Histologic examination revealed significant fibrosis in all resected specimens and two complete responses. Surgical margins were negative in 72%, and lymph nodes were negative in 70% of resected patients. Median survival in resected patients has not been reached at a median follow-up of 16 months. Conclusions: Neoadjuvant CRT provided an opportunity for patients with occult metastatic disease to avoid the morbidity of resection and resulted in tumor downstaging in a minority of patients with LA tumors. Survival after neoadjuvant CRT and resection appears to be at least comparable to survival after resection and adjuvant (postoperative) CRT.

AB - Background: The use of neoadjuvant (preoperative) chemoradiotherapy (CRT) for pancreatic cancer has been advocated for its potential ability to optimize patient selection for surgical resection and to downstage locally advanced tumors. This article reports our experience with neoadjuvant CRT for localized pancreatic cancer. Methods: Since 1995, 111 patients with radiographically localized, pathologically confirmed pancreatic adenocarcinoma have received neoadjuvant external beam radiation therapy (EBRT; median, 4500 cGy) with 5-flourouracil-based chemotherapy. Tumors were defined as potentially resectable (PR, n = 53) in the absence of arterial involvement and venous occlusion and locally advanced (LA, n = 58) with arterial involvement or venous occlusion by CT. Results: Five patients (4.5%) were not restaged due to death (n = 3) or intolerance of therapy (n = 2). Twenty-one patients (19%) manifested distant metastatic disease on restaging CT. Twenty eight patients with initially PR tumors (53%) and 11 patients with initially LA tumors (19%) were resected after CRT. Histologic examination revealed significant fibrosis in all resected specimens and two complete responses. Surgical margins were negative in 72%, and lymph nodes were negative in 70% of resected patients. Median survival in resected patients has not been reached at a median follow-up of 16 months. Conclusions: Neoadjuvant CRT provided an opportunity for patients with occult metastatic disease to avoid the morbidity of resection and resulted in tumor downstaging in a minority of patients with LA tumors. Survival after neoadjuvant CRT and resection appears to be at least comparable to survival after resection and adjuvant (postoperative) CRT.

KW - Adenocarcinoma

KW - Chemoradiotherapy

KW - Neoadjuvant therapy

KW - Pancreas

UR - http://www.scopus.com/inward/record.url?scp=18244369036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244369036&partnerID=8YFLogxK

U2 - 10.1245/aso.2001.8.10.758

DO - 10.1245/aso.2001.8.10.758

M3 - Article

C2 - 11776488

AN - SCOPUS:18244369036

VL - 8

SP - 758

EP - 765

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 10

ER -